Oncoclínicas do Brasil Serviços Médicos S.A. (ONCO3) Earnings Call Transcripts
Oncoclínicas do Brasil Serviços Médicos S.A.'s Latest Earnings Call - Q1 FY2026
Oncoclínicas do Brasil Serviços Médicos S.A. reported its Q1 2026 results, highlighting significant operational and financial pressures. Revenue was impacted by a BRL 40 million shortfall due to medication supply issues, and net revenue fell significantly due to a one-time PCLD adjustment. Despite these challenges, management emphasized strategic initiatives to stabilize operations and improve profitability. No changes in forward guidance were provided, but management remains focused on long-term sustainability.
Reported metrics
| Metric | Value |
|---|---|
| Revenue Impact | BRL 40 million (miss) |
| Net Revenue | Significant decline (miss) |
| Gross Margin | 27.7% (miss) |
| EBITDA Margin | 8.7% (miss) |
| Net Debt to EBITDA | 5.2x (miss) |
Guidance from management
No specific forward guidance was provided. Management emphasized ongoing efforts to stabilize operations and improve profitability over time.
What analysts pressed on
Analysts did not raise questions during the call, but potential concerns could include the impact of medication supply issues on future revenue and the company's ability to manage its increased leverage.
Main topics on the call
- Operational and Financial Pressures — The company faced 'strong operational pressure and financial pressure' due to medication supply issues, impacting revenue by BRL 40 million. Management is focused on 'preserving continuity and maintaining sustainability....
- Medication Supply Issues — A lack of medication supply in certain regions led to a reduction in procedures and a BRL 40 million revenue impact. Management is working with partners like Lumina and OncoProd to address these issues.
- PCLD Adjustment — A significant one-time PCLD adjustment increased provisions to nearly 100% of accounts receivable, impacting net revenue. Management expects this to normalize to 3% in future quarters.
- Cost Management Initiatives — The company implemented a zero-based budget and renegotiated supplier contracts, resulting in a reduction of operating expenses. This is expected to continue in future quarters.
Read the full Oncoclínicas do Brasil Serviços Médicos S.A. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Oncoclínicas do Brasil Serviços Médicos S.A.
Oncoclínicas do Brasil Serviços Médicos S.A. (ONCO3) is a publicly listed company in the Health Care Providers and Services industry, within the Health Care sector. It trades on BOVESPA and is based in BR. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 14 calls on record spanning August 17, 2021 to May 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 14 Oncoclínicas do Brasil Serviços Médicos S.A. earnings call transcripts on record, spanning August 17, 2021 to May 15, 2026. Based on this history, Oncoclínicas do Brasil Serviços Médicos S.A. reports semi-annually. The most recent call on file is dated May 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ONCO3
- Exchange
- BOVESPA
- Country
- BR
- Sector
- Health Care
- Calls on record
- 14
- First call
- August 17, 2021
- Most recent
- May 15, 2026
- Reporting cadence
- semi-annually
| Quarter | Date | |
|---|---|---|
| Q1 FY2026 | May 15, 2026 | Read transcript → |
| Q4 FY2025 | Apr 10, 2026 | Read transcript → |
| Q3 FY2025 | Nov 17, 2025 | Read transcript → |
| Q4 FY2024 | Mar 28, 2025 | Read transcript → |
| Q2 FY2024 | Aug 14, 2024 | Read transcript → |
| Q1 FY2024 | May 14, 2024 | Read transcript → |
| Q3 FY2023 | Nov 14, 2023 | Read transcript → |
| Q2 FY2023 | Aug 15, 2023 | Read transcript → |
| Q1 FY2023 | May 16, 2023 | Read transcript → |
| Q2 FY2022 | Aug 16, 2022 | Read transcript → |
| Q1 FY2022 | May 17, 2022 | Read transcript → |
| Q4 FY2021 | Mar 30, 2022 | Read transcript → |
| Q3 FY2021 | Nov 17, 2021 | Read transcript → |
| Q2 FY2021 | Aug 17, 2021 | Read transcript → |